Path: Home > YY/T > Page2 > YY/T 1224-2014

Price & Delivery

US$209.00 · In stock · Download in 9 seconds
YY/T 1224-2014: Detection kit for analysis of related chromosome and gene abnormalities in bladder cancer (Fluorescent in situ hybridization)
Delivery: 9 seconds. True-PDF full-copy in English & invoice will be downloaded + auto-delivered via email. See step-by-step procedure
Status: Valid

Std ID	Version	USD	Buy	Deliver [PDF] in	Title (Description)
YY/T 1224-2014	English	209	Add to Cart	3 days [Need to translate]	Detection kit for analysis of related chromosome and gene abnormalities in bladder cancer (Fluorescent in situ hybridization)

YY/T 1224-2014: Detection kit for analysis of related chromosome and gene abnormalities in bladder cancer (Fluorescent in situ hybridization)

---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
Detection kit for analysis of related chromosome and gene abnormalities in bladder cancer (Fluorescent in situ hybridization) ICS 11.100 C44 People's Republic of China pharmaceutical industry standards Bladder cancer and related chromosome Gene abnormality detection kit (fluorescence in situ hybridization) geneabnormalitiesinbladdercancer (Fluorescentinsituhybridization) Issued on. 2014-06-17 2015-07-01 implementation China Food and Drug Administration released

Foreword

This standard was drafted in accordance with GB/T 1.1-2009 given rules. Please note that some of the content of this document may involve patents. Release mechanism of the present document does not assume responsibility for the identification of these patents. This standard was proposed by the China Food and Drug Administration. This standard by the national medical clinical laboratory testing and in vitro diagnostic systems for Standardization Technical Committee (SAC/TC136) centralized. This standard was drafted. Chinese Academy of Food and Drug test. The main drafters of this standard. Huang Ying, Shen Shu, Zhangchun Tao, noble first. Bladder cancer and related chromosome Gene abnormality detection kit (fluorescence in situ hybridization)

1 Scope

This standard specifies the bladder cancer-related chromosomal abnormality detection kit (fluorescence in situ hybridization) the definition and composition, to Requirements, test methods, marking, labeling, instructions, packaging, transport and storage. This standard applies to the CSP3, CSP7, CSP17, GLP9 corresponding sites of four kinds of fluorescence in situ hybridization probe and counterstain composed by Test sample (usually urine smears) on the 3rd, 7th, 17th chromosome aneuploidy increases and P16 gene locus on chromosome 9 Missing the point, so the diagnosis of bladder cancer kits. This standard does not apply to. a) In immunohistochemistry diagnostic methods as the basic principle for bladder cancer diagnosis kit; Labeled Immunoassays b) by ELISA analysis as the basic principle for bladder cancer diagnosis kit.

2 Normative references

The following documents for the application of this document is essential. For dated references, only the dated version suitable for use herein Member. For undated references, the latest edition (including any amendments) applies to this document. GB/T 191 Packaging - Pictorial signs

3 Terms and Definitions

The following terms and definitions apply to this document. 3.1 Fluorescence in situ hybridization fluorescentinsituhybridization; FISH According to the principle of complementary base pairing with the target nucleic acid fragment DNA pairing (probe) on the labeling fluorescent dye, and the probe is to be tested Nucleic acid fragments corresponding materials under certain conditions specific binding (hybridizing) to form a double-stranded nucleic acid, fluorescence microscopy and recorded by means of shape A type of hybrid duplexes, the number, the sample to be tested to determine whether or not the normal method for detecting target DNA. 3.2 Bladder cancer-related chromosomal abnormalities and gene detection kit (fluorescence in situ hybridization) detectionkitforanalysisof relatedchromosomeandgeneabnormalitiesinbladdercancer (fluorescentinsituhybridization) By the CSP3, CSP7, CSP17 and GLP9 corresponding sites of a total of four kinds of fluorescence in situ hybridization probes (hereinafter referred to as. Probe) and counterstain And other auxiliary agents composed by the 3rd detected sample to be tested, No. 7, No. 17 chromosome aneuploidy and increased chromosome 9 P16 group Due to lack of sites for bladder cancer diagnosis kit (hereinafter. the kit).

4 Requirements

4.1 Appearance The kit packaging should be complete, no damage, marked complete, clear; each liquid reagent should be clearly labeled, leak-free, color should be consistent with the manufacturer ...